Myriad Genetics
MYGN
284 hedge funds and large institutions have $3.48B invested in Myriad Genetics in 2018 Q3 according to their latest regulatory filings, with 56 funds opening new positions, 93 increasing their positions, 83 reducing their positions, and 28 closing their positions.
100% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 28
27% more capital invested
Capital invested by funds: $2.75B → $3.48B (+$729M)
12% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 83
10% more funds holding
Funds holding: 258 → 284 (+26)
1.43% more ownership
Funds ownership: 105.08% → 106.52% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
55% less call options, than puts
Call options by funds: $9.89M | Put options by funds: $22.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$73.2M |
| 2 |
Millennium Management
New York
|
+$28.3M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$18M |
| 4 |
Morgan Stanley
New York
|
+$17.2M |
| 5 |
BlackRock
New York
|
+$17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$56.1M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$21.5M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$19M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$18.4M |
| 5 |
Goldman Sachs
New York
|
-$15.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
STA
301
Summit Trail Advisors
New York
| – | -$50K | -1,350 | Closed |
|
|
S
302
SignatureFD
Atlanta,
Georgia
| – | -$11K | -285 | Closed |
|
|
KCPG
303
Kavar Capital Partners Group
Leawood,
Kansas
| – | -$7K | -200 | Closed |
|
|
LYV
304
Live Your Vision
West Conshohocken,
Pennsylvania
| – | -$9K | -200 | Closed |
|
|
GBBWRPM
305
Genovese Burford & Brothers Wealth & Retirement Plan Management
Sacramento,
California
| – | -$5K | -144 | Closed |
|
306
Parallax Volatility Advisers
San Francisco,
California
| – | -$4K | -119 | Closed |
|
|
CF
307
Centaurus Financial
Anaheim,
California
| – | -$4K | -111 | Closed |
|
|
MWM
308
MinichMacGregor Wealth Management
Saratoga Springs,
New York
| – | -$1K | -50 | Closed |
|
|
ACS
309
Archford Capital Strategies
Swansea,
Illinois
| – | -$1K | -15 | Closed |
|
|
JA
310
JOYN Advisors
Atlanta,
Georgia
| – | +$222 | +5 | New |
|
MYGN Hedge Fund Activity: Q3 2018 in Review
284 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q3 2018, worth a combined $3.48B — up 27% from $2.75B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new MYGN positions and 28 closed out — a net gain of 28 holders — while 93 added to existing stakes and 83 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $73.2M. The largest seller was Camber Capital Management, exiting entirely with an estimated $56.1M sold.
- 284 institutional investors held Myriad Genetics (MYGN) as of Q3 2018, up from 258 in Q2 2018.
- Funds reported $3.48B of Myriad Genetics stock for Q3 2018, up 27% quarter-over-quarter.
- 56 funds opened new Myriad Genetics positions in Q3 2018 and 28 closed out, a net change of +28 holders.
- The largest Myriad Genetics buyer in Q3 2018 was Consonance Capital Management, an estimated $73.2M added.
- The largest Myriad Genetics seller in Q3 2018 was Camber Capital Management, an estimated $56.1M sold.
Based on aggregated 13F filings for Q3 2018.